Dr Ryan O’Hare Doig, Head, Spinal Cord injury Research (SAHMRI)
Neil Sachse Centre for Spinal Cord Research (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
Dr. Ryan O’Hare Doig’s early research career has focused on understanding the pathophysiology of secondary degeneration following neurotrauma to the central nervous system (CNS). He uses innovative analytical techniques to demonstrate biochemical, molecular and gross anatomical changes that occur following CNS injury. Dr. O’Hare Doig has developed and optimised a combinatorial treatment strategy incorporating pharmacotherapeutics for the treatment of CNS injury. Ryan’s combinatorial strategy has been assessed in a clinically relevant model of spinal cord injury (SCI), demonstrating significant functional recovery and tissue sparing, crucial for the translation of his research into clinical trials.
In 2017, Ryan joined the South Australian Health & Medical Research Institute (SAHMRI) and the Neil Sachse Centre for Spinal Cord Research, to provide his expertise in SCI and other neurotrauma models. Dr. O’Hare Doig’s lab looks to help develop new techniques to provide a more accurate diagnosis and prognosis of SCI, and to identify potential treatment strategies in a clinical setting.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.
